Cancer biology research links YAP and TAZ hyperactivation to immune evasion by coupling genomic instability with increased PD-L2 expression. The dataset describes findings that YAP/TAZ-driven instability can expose tumors to immune cells while simultaneously elevating PD-L2 to suppress T-cell attack. The work positions YAP/TAZ as a dual driver of tumor immunogenicity and immune checkpoint upregulation, supporting combined targeting strategies in future preclinical or translational work. No clinical trial endpoints were provided in the dataset.